ClinicalTrials.gg
CompletedNCT07782034Updated Aug 24, 2026

40-Hz Audiovisual Stimulation in Schizophrenia Spectrum Disorders

An interventional study of 40-Hz Binaural Beat Music Combined With 40-Hz Rhythmic Photic Stimulation and Sham group in Anxiety, sponsored by National Cheng Kung University. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-24.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by National Cheng Kung University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Feb 2024, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

This randomized, sham-controlled trial evaluated the effects of 40-Hz binaural beat music (BBM) combined with 40-Hz rhythmic photic stimulation (RPS) in adults with schizophrenia spectrum disorders. A total of 55 participants with schizophrenia or schizoaffective disorder were randomly assigned to either the BBM plus RPS group or a sham control group. Participants received 20-minute sessions three times per week for 12 consecutive weeks, for a total of 36 sessions. The primary outcome was anxiety measured using the Beck Anxiety Inventory (BAI). Secondary outcomes included psychological distress measured using the Five-item Brief Symptom Rating Scale (BSRS-5) and global cognitive function measured using the Mini-Mental State Examination (MMSE). Electroencephalographic (EEG) relative power across delta, theta, alpha, beta, and gamma frequency bands was also assessed as an exploratory physiological outcome.

02

Conditions studied

  • Anxiety

Browse trials for

03

In context

Anxiety Disorders Unverified

7,207 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.

This study's enrollment of 55 is below the median of 80 across 6,062 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

National Cheng Kung University is the lead sponsor of 63 studies on the registry; 12 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of schizophrenia or schizoaffective disorder according to criteria, made by a board-certified psychiatrist at least 1 year prior to enrollment.
  2. Age 20 to 60 years.
  3. Stable psychiatric symptoms, with no adjustment of major psychotropic medications for at least 2 consecutive months.
  4. No severe hearing impairment.

4. Current participation in a day-care program, community rehabilitation center, or rehabilitation ward.

Exclusion criteria

Exclusion Criteria:

  1. Acute illness episode or unstable physical condition.
  2. History of epilepsy or risk of seizures.
  3. Substance abuse.
  4. Impaired or disturbed consciousness.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    BBM and RPS group

    Participants assigned to the BBM and RPS group received combined 40-Hz binaural beat music (BBM) and 40-Hz rhythmic photic stimulation (RPS). During each session, participants wore circumaural stereo headphones and RPS glasses and received 20 minutes of relaxing music embedded with 40-Hz binaural beats while simultaneously receiving 40-Hz rhythmic photic stimulation with their eyes closed. The binaural beats were generated using 200-Hz and 240-Hz carrier tones and delivered at 60-65 dB SPL. The RPS glasses delivered bilateral white LED stimulation at 40 Hz using a square-wave pattern with a 50% duty cycle and an illuminance of 400 lx. Sessions were administered three times per week for 12 consecutive weeks, for a total of 36 sessions.

    Other: 40-Hz Binaural Beat Music Combined With 40-Hz Rhythmic Photic Stimulation

  • Placebo comparator
    Sham group

    Participants assigned to the sham group underwent the same session procedures as the intervention group. During each session, participants wore circumaural stereo headphones and RPS glasses and listened to the same relaxing music for 20 minutes with their eyes closed. However, the music contained no binaural beats, and the light-output module of the RPS glasses was switched off so that no rhythmic photic stimulation was delivered. To maintain a similar device appearance, the RPS glasses were powered on with the power indicator illuminated. Music tracks, sound volume, session duration, and other environmental conditions were identical to those of the intervention group. Sessions were administered three times per week for 12 consecutive weeks, for a total of 36 sessions.

    Other: Sham group

Interventions

  • Other40-Hz Binaural Beat Music Combined With 40-Hz Rhythmic Photic Stimulation

    Participants received simultaneous 40-Hz binaural beat music (BBM) and 40-Hz rhythmic photic stimulation (RPS). The BBM was generated using 200-Hz and 240-Hz carrier tones to produce a 40-Hz binaural beat and was embedded in relaxing music delivered through circumaural stereo headphones at 60-65 dB SPL. The RPS was delivered through glasses equipped with bilateral white LEDs producing a 40-Hz square-wave flicker with a 50% duty cycle and an illuminance of 400 lx. Participants received the combined auditory and visual stimulation for 20 minutes per session with their eyes closed, three times per week for 12 consecutive weeks, for a total of 36 sessions.

  • OtherSham group

    Participants in the sham group underwent the same session procedures as the intervention group but did not receive 40-Hz binaural beat stimulation or rhythmic photic stimulation. Participants wore circumaural stereo headphones and RPS glasses and listened to the same relaxing music for 20 minutes; however, the music contained no binaural beats, and the light-output module of the RPS glasses remained switched off so that no flickering light was delivered. The glasses were powered on with the power indicator illuminated to maintain a similar device appearance. Music tracks, sound volume, session duration, and environmental conditions were identical to those of the intervention group. Sessions were administered three times per week for 12 consecutive weeks, for a total of 36 sessions.

06

What researchers measure

Primary outcomes

  1. Change in Anxiety Severity as Measured by the Beck Anxiety Inventory (BAI)

    The Beck Anxiety Inventory (BAI) is a 21-item self-report measure used to assess the severity of anxiety symptoms. Each item is rated from 0 to 3, yielding a total score ranging from 0 to 63, with higher scores indicating greater anxiety severity. The primary outcome was the change in total BAI score from baseline to post-intervention.

    Time frame: Baseline and within 2 days after completion of the 12-week intervention

07

Study locations

1 site
  • Asia Univeraity
    Taichung, WuFeng 41354, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jun 2024, 4 months.

Of 3,841 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 4 months is below that.

Counting every sponsor, half of 3,943 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Aug 24, 2026
StartActual
Feb 1, 2024
Primary completionActual
Jun 30, 2024
CompletionActual
Jul 30, 2024
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07782034
Lead sponsor
National Cheng Kung University
Responsible party
Yang Shang-Yu (Associate professor, National Cheng Kung University) — Principal investigator
First posted
Aug 24, 2026
Start date
Feb 1, 2024
Primary completion
Jun 30, 2024
Completion
Jul 30, 2024
Last update
Aug 24, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion